Evaluation of Copeptin as a novel marker for predicting the prognosis of fatty liver disease and its complications in obesity

Objectives: Copeptin is an independent, persistent plasma marker for vasopressin (VP) linked to all aspects of the metabolic syndrome and overweight. The study aimed to evaluate copeptin levels as a surrogate marker for predicting liver disorders in obese patients. Methods: cross sectional study include 20 obese males with mean of age (42.50± 3.17) years and 20 obese females with mean of ages (44.55±2.82) years, the plasma copeptin level was masured and related with fatty liver disease according to a validated liver enzyme, lipid profile, BMI and abdominal ultrasound. Results: Highly significant increase liver enzyme, lipid profile and BMI in both males and females obese fatty liver patients, significant elevated Copeptin concentration in both gender (13.84±0.27), (13.88±0.40) and highly significant positive correlated with ferritin, BMI and TC, (r=0.651, 0.496, 0.491 and 0.457), while showed Copeptin significant negative correlated with HDL (-0.508, -0.490). Conclusions: obese individuals with the fatty liver disease showed associated with highly increased plasma copeptin, also this marker considers a useful tool for the diagnostic pathway to risk factors of metabolic disease such as diabetes mellitus although this hypothesis needs further studies to be confirmed.